Drug Trial Radar · NCT05513560
RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine
Last checked: Nov 19, 2026Latest source record: Feb 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
460
Actual
Start
May 31, 2023
Primary completion
Mar 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- University Health Network, TorontoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The researchers propose to develop a Canada-wide, adaptive randomized clinical platform trial to assess the effectiveness of various interventions in patients with lingering symptoms of COVID-19 ("Long COVID"). Participants will be randomized initially to 1 of 3 arms, including placebo (control) and 2 interventions. Because this is an adaptive trial, arms can be dropped if found to be ineffective and new arms can be added. Interventions will last for 2 months and participants will be followed for an additional 4 months (6 months total). Approximately 800-1000 patients with Long COVID will be recruited across Canada. Results from this trial will accelerate the availability of high-quality, real-time evidence and solutions to enable Canada to improve the clinical care of patients with Long COVID.
Conditions
- Long COVID
- Post COVID Condition
- Post Acute Sequelae of COVID-19
Interventions
IbudilastDrug
10mg pills, 2 pills twice per day
PentoxifyllineDrug
400mg pill 3 times per day
PlaceboOther
Placebo matching ibudilast, 2 pills twice per day OR placebo matching pentoxifylline 1 pill 3 time per day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- SF-36 physical component score (PCS)Time frame: from baseline to two months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
The Ottawa Hospital
Ottawa, Ontario, Canada
University Health Network, Osteoporosis Department
Toronto, Ontario, Canada
Mount Sinai Hospital
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.